MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children.
Allergy
; 71(8): 1219-22, 2016 08.
Article
en En
| MEDLINE
| ID: mdl-27043452
ABSTRACT
The objective was to evaluate the efficacy of MP-AzeFlu (Dymista(®) ) vs fluticasone propionate (FP), (both 1 spray/nostril bid), in children with allergic rhinitis (AR). MP-AzeFlu combines azelastine hydrochloride, FP and a novel formulation in a single spray. Children were randomized in a 3 1 ratio to MP-AzeFlu or FP in this open-label, 3-month study. Efficacy was assessed in children aged ≥ 6 to <12 years (MP-AzeFlu n = 264; FP n = 89), using a 4-point symptom severity rating scale from 0 to 3 (0 = no symptoms; 3 = severe symptoms). Over the 3-month period, MP-AzeFlu-treated children experienced significantly greater symptom relief than FP-treated children (Diff -0.14; 95% CI -0.28, -0.01; P = 0.04), noted from the first day (particularly the first 7 days) and sustained for 90 days. More MP-AzeFlu children achieved symptom-free or mild symptom severity status, and did so up to 16 days faster than FP. MP-AzeFlu provides significantly greater, more rapid and clinically relevant symptom relief than FP in children with AR.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Antialérgicos
/
Rinitis Alérgica
/
Fluticasona
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
Límite:
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Allergy
Año:
2016
Tipo del documento:
Article
País de afiliación:
Estados Unidos